Combo Disappoints in Metastatic Prostate Cancer
Combining the tyrosine kinase inhibitor saracatinib with docetaxel does not benefit patients with metastatic, castration-resistant prostate cancer (mCRPC), according to
Read more
Combining the tyrosine kinase inhibitor saracatinib with docetaxel does not benefit patients with metastatic, castration-resistant prostate cancer (mCRPC), according to
Read moreBill Turnbull, 64, was told by doctors he had prostate cancer back in March 2018. Since then, the presenter has
Read moreProstate cancer is cancer that occurs in the prostate — a small walnut-shaped gland in men, and it mainly affects
Read moreBlocking a kinase known as CDK7 sets off a chain reaction that results in the death of prostate cancer cells
Read moreCellular soldiers created using the body’s own defenses can track down and kill escaping cancer cells during surgeries, preventing metastasis
Read moreIn a study using yeast cells and data from cancer cell lines, Johns Hopkins University scientists report they have found
Read moreA new reusable device created by the Johns Hopkins University can help women with breast cancer in lower income countries
Read moreUntil now, researchers believed recurrent mutations (hotspot mutations) in cancer tumors were the important mutations (driver mutations) that promoted cancer
Read moreMRI instead of PSA A new method for the diagnosis of prostate cancer is tested. The promising Test could be
Read moreResearchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta known
Read more